MannKind Corp. Stock
MannKind Corp. Stock
MannKind Corp. shows a slight decrease today, losing -€0.014 (-0.410%) compared to yesterday.
The stock is an absolute favorite of our community with 28 Buy predictions and no Sell predictions.
Based on the current price of 3.36 € the target price of 7 € shows a potential of 108.46% for MannKind Corp. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for MannKind Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of MannKind Corp. in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
C******** o* t** e**********
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of MannKind Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| MannKind Corp. | -0.410% | -1.928% | -10.262% | -1.002% | -31.914% | -16.778% | -3.228% |
| Evolus Inc | -0.040% | -0.496% | -14.130% | -33.154% | -4.330% | -42.703% | -41.085% |
| Heron Therapeutics Inc. | -1.990% | 2.964% | 15.558% | -71.508% | -61.329% | -69.229% | -95.846% |
| Rhythm Pharmaceuticals | -1.080% | 1.667% | -5.181% | 26.207% | -2.139% | 479.114% | 535.417% |
Comments
MannKind (MNKD) had its "overweight" rating reaffirmed by Wells Fargo & Company.
Show more
Ratings data for MNKD provided by MarketBeat
MannKind (MNKD) had its "buy" rating reaffirmed by HC Wainwright.
Show more
Ratings data for MNKD provided by MarketBeat
MannKind (MNKD) had its "overweight" rating reaffirmed by Wells Fargo & Company.
Show more
Ratings data for MNKD provided by MarketBeat
News
MannKind’s Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underway
Key Points
- Interested in MannKind Corporation? Here are five stocks we like better.
- MannKind’s Phase 1b trial met its short-term safety and tolerability objective in 27 IPF patients, with no
MannKind Wins FDA Approval for Furoscix ReadyFlow, Secures $50M PIPE
Key Points
- Interested in MannKind Corporation? Here are five stocks we like better.
- MannKind received FDA approval for Furoscix ReadyFlow, an auto-injector that delivers an 80 mg dose of
What This MannKind Filing Reveals About Three Years of Underperformance
Sanjay R. Singh, EVP Technical Operations at MannKind Corporation (NASDAQ:MNKD), disposed of 46,795 shares of common stock on July 15, 2026, as disclosed in a recent SEC Form 4 filing.
Transaction
